Published in Biotech Business Week, May 19th, 2003
A topical, twice-daily, nonsteroidal anti-inflammatory solution, bromfenac is initially being developed for the treatment of ocular inflammation following cataract surgery. The phase III study is expected to commence during the second quarter of 2003 and take place at more than 25 treatment centers in the U.S.
"Following initiation of the phase III study, bromfenac will become ISTA's third product candidate in phase III or beyond, a significant milestone...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.